Home > Financial Ratios > GLAND PHARMA
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results

GLAND PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   Core EBITDA Growth(%) -1.3818.82-27.0420.6731.28

What is the latest Core EBITDA Growth ratio of GLAND PHARMA ?

The latest Core EBITDA Growth ratio of GLAND PHARMA is -1.38 based on Mar2025 Consolidated results.
Year Core EBITDA Growth
Mar2025-1.38
Mar202418.82
Mar2023-27.04
Mar202220.67
Mar202131.28

How is Core EBITDA Growth of GLAND PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2025 -1.38
Negative
Mar2024 18.82
Positive
Mar2023 -27.04
Negative
Mar2022 20.67
-33.92
Mar2021 31.28 -

Other Financial Ratios of GLAND PHARMA


Compare Core EBITDA Growth ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹27,505.1 Cr -8.5% -11.5% 9.8% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹431,628.0 Cr 3.5% 5.6% 11.9% Stock Analytics
DIVIS LABORATORIES ₹167,975.0 Cr -1.3% 4.5% 16.2% Stock Analytics
TORRENT PHARMACEUTICALS ₹145,804.0 Cr -0.7% 6.9% 47.8% Stock Analytics
DR REDDYS LABORATORIES ₹108,829.0 Cr 1.3% 5.1% 17.5% Stock Analytics
CIPLA ₹106,768.0 Cr -1.9% -0.3% -6% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

-8.5%

-11.5%

9.8%

SENSEX

-4.1%

-5.8%

5.8%


You may also like the below Video Courses